The Pharmaceutical sector remains in a state of transition. Cost pressures and technological advancements are driving considerable volumes of mergers and acquisitions as the global shift re-shapes real estate strategies and portfolio allocations.
With pharmaceutical companies being forced to address business strategies throughout a period of industry transition, careful consideration and management is required to maximize growth potential from real estate portfolios.
This latest Cushman & Wakefield pharmaceutical briefing addresses:
Are Mergers & Acquisitions (M&A) complicating the real estate picture?
Although the hope of greater efficiency is a major motivation for M&A activity which continues to gather pace, some companies overlook or mismanage a major source of potential value, the corporate real estate portfolio.
The importance of attracting and retaining talent
From fostering collaboration, to simply increasing the amount of natural light, choosing the right spaces in the right places can be a powerful tool in talent recruitment and retention, greater innovation and productivity.
The rise of biologics and implications for out dated facilities
With so much of today’s growth coming from biotech medicines, traditional pharmaceutical manufacturing facilities are quickly becoming out of date. How are corporates addressing the changes and what are the most cost-effective options when addressing real estate strategies.
Attraction of growth markets and predictions for 2015.
How the evolving pharmaceutical landscape is shaping real estate strategies, understanding the risks and opportunities of entering new markets and what are our predictions for 2015.
Access the full market data